Interleukin-1β (rs 1143627 T/C) Gene Polymorphism May Increase the Risk of Developing LDD in Turkish Population
NCT ID: NCT05601739
Last Updated: 2022-11-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
94 participants
OBSERVATIONAL
2019-04-08
2020-04-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Epigenetic and Molecular Biomarkers in Chronic Low Back Pain and Modic Changes
NCT03406624
Serum Cytokine Levels in Patients with Lumbal Disc Herniation and Effectiveness of Exercise
NCT04912388
Correlation Between RMI of Degenerative Disk Disease and Reduction of Pain After Disk-infiltration Treatments
NCT04142580
Lumbar Transforaminal Anterior Epidural Steroid Injections in Discogenic Low Back Pain
NCT04930211
Identification of Biomarkers and Molecular Targets Involved on Intervertebral Disc Degeneration and Discogenic Pain
NCT06349226
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Aims: This study aims to show the association between the Interleukin-1β (rs 1143627 T/C) gene polymorphism and the patient's pain level, radiological features, functional disability, and spinal flexibility.
Method: A hospital-based case-control study included 50 LDD patients and 44 healthy controls. In this study, Taqman allelic discrimination analysis was performed for the genotype of the Interleukin-1β (rs 1143627 T/C) gene polymorphism. Differences in Interleukin-1β allele frequencies and genotypes were evaluated between patients and controls. Relationships between allele presence/genotype and disease risk are reported as odds ratios (ORs) with 95% confidence intervals (CIs). The Pfirrmann classification was used to grade the level of disc degeneration on MRI scans, and the McNab's classification was used to classify disc displacements. The pain levels of the patient group were evaluated with VAS and their functional disability with ODI. Spinal flexibility was evaluated using the Modified Schober method and a digital inclinometer.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lumbar degenerative disc disease
The case group was made of 50 patients, 24 women (48%) and 26 men (52%) with several clinical symptoms suggestive of LDD and the condition confirmed by MRI.
No interventions assigned to this group
Healthy
The control group was made of 44 healthy volunteers.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18-60 years old
* With magnetic resonance imaging (MRI) evidencing LDD with Pfirrmann classification
Exclusion Criteria
* Lumbar spinal stenosis
* Spinal deformities (scoliosis, kyphosis, spondylolisthesis)
* Vertebral fractures
* Inflammatory rheumatic diseases
* Diabetic neuropathy
* Pregnancy
* Drug and alcohol dependence
* Psychiatric illness
* Oncologic diseases
* Who refuse to sign the consent form and donate a blood sample for analysis of genomic DNA.
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yeditepe University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dilek Ünsal, M.S.c
Role: PRINCIPAL_INVESTIGATOR
Yeditepe University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yeditepe University
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YeditepeU-DilekÜ-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.